{"id":"W4387811279","doi":"10.1016/j.annonc.2023.09.2168","title":"1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"Regeneron Pharmaceuticals; EMD Serono; Takeda Pharmaceuticals U.S.A.; Genentech; Amgen","keywords":"Medicine; Sting; Cytokine; Adverse effect; Pharmacology; Cytokine release syndrome; Internal medicine; Oncology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001153676,0.0002648552,0.0009044593,0.0006938531,0.00009879655,0.00001036445,0.0001077911,0.0001216291,0.00001867853],"category_scores_gemma":[0.00051648,0.0002094526,0.00003058156,0.0004803836,0.0001545682,0.00033852,0.0001277737,0.0002869643,0.000002460674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007524963,"about_ca_system_score_gemma":0.0001955278,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001837447,"about_ca_topic_score_gemma":0.001075254,"domain_scores_codex":[0.9973086,0.0008879062,0.0007712634,0.0004713929,0.00006531981,0.0004955187],"domain_scores_gemma":[0.9981388,0.0009423096,0.0005381704,0.0001902949,0.0001593645,0.00003108923],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.541673,0.0209696,0.06399483,0.0004655664,0.0002656891,0.0003292459,0.01070869,0.0001868815,0.1188167,0.00002881781,0.000137005,0.2424239],"study_design_scores_gemma":[0.1025931,0.08882054,0.7732328,0.0005194779,0.00006426161,0.0001050804,0.005508841,0.0008078147,0.02780161,0.00007192419,0.0001054465,0.0003690457],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966651,0.0001058103,0.00004161273,0.0005533549,0.00006523553,0.002475163,0.00003773399,0.00002834066,0.00002765629],"genre_scores_gemma":[0.9991341,0.0001010106,0.000134967,0.00008363504,0.000002712347,0.0002776191,0.0001711941,0.00002766349,0.00006707225],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.709238,"threshold_uncertainty_score":0.8541228,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04695138383112311,"score_gpt":0.3784341755660882,"score_spread":0.331482791734965,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}